Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    Terminalia ferdinandiana Exell. Kino Extracts have Anti-Giardial Activity and Inhibit Caco2 and HeLa Cancer Cell Proliferation

    wadmin2By wadmin2April 9, 2018Updated:August 12, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Joseph Shalom1,2, Paran Rayan1,2, Reece Courtney1,2, Pauline Ann McDonnell2, Ian Edwin Cock1,2*
    1Environmental Futures Research Institute, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, Australia.
    2School of Natural Sciences, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, Australia.

    Pharmacognosy Communications,2018,8,2,60-65.
    DOI: 10.5530/pc.2018.2.13
    Published: January 2018
    Type: Original Article

    ABSTRACT

    Introduction: Terminalia ferdinandiana Exell. is an endemic Australian plant which is known for its exceptionally high antioxidant content. The fruit is a nutritional food and the leaves and kinos were used in Australian Aboriginal medicine to treat a variety of diseases. However, T. ferdinandiana kinos remain largely unexamined for their medicinal properties. Methods: Solvent extracts were prepared from T. ferdinandiana kinos and their antiproliferative activities against G. duodenalis and were determined by direct enumeration. The anti-proliferative activities against HeLa and Caco2 cancer cell lines were determined using an MTS based cell assay. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: Methanolic and aqueous T. ferdinandiana kino extracts were strong inhibitors of Caco2 and HeLa cell proliferation, with IC50 values substantially below 1000 μg/mL. In contrast, the mid to lower polarity solvent extractions (ethyl acetate, chloroform and hexane) were less potent inhibitors of cell proliferation. The aqueous and methanolic extracts were also effective inhibitors of G. duodenalis proliferation, albeit with slightly higher IC50 values than against the Caco2 and HeLa cells. All T. ferdinandiana kino extracts were nontoxic in the Artemia franciscana bioassay, with LC50 values substantially >1000 μg/mL. Conclusion: The antiproliferative activity of the T. ferdinandiana kino extracts against G. duodenalis and the HeLa and Caco2 cancer cell lines indicates their potential in the treatment and prevention of giardiasis and some cancers.

    Key words: Kakadu plum, Combretaceae, Giardia duodenalis, Anticancer activity, Antiproliferative activity, Caco2, HeLa, Apoptosis.

    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up